Is delayed re-endothelialization with rapamycin-coated stents rescued by the addition of a glycogen synthase kinase-3beta inhibitor?
GSKi efficiently ameliorates the vascular response to stent implantation and has an important redeeming effect on the deleterious endothelial effects of rapamycin-coated stents.
Our results indicate that homozygous Gly-16 patients using occasional salbutamol have reduced responsiveness to formoterol in terms of bronchoprotection to AMP than patients not using salbutamol. Patients expressing the homozygous gly-16 genotype of the beta(2)-adrenoceptor genotype receiving a LABA may benefit from the substitution of their usual SABA for an alternative reliever.